JOYCE HISAE YAMAMOTO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease(2020) URZUA, Cristhian A.; HERBORT JR., Carl; VALENZUELA, Rodrigo A.; EL-ASRAR, Ahmed M. Abu; ARELLANES-GARCIA, Lourdes; SCHLAEN, Ariel; YAMAMOTO, Joyce; PAVESIO, CarlosPurpose To describe distinctive stages of Vogt-Koyanagi-Harada (VKH) disease: initial-onset acute versus chronic recurrent disease. Methods A comprehensive literature review regarding stages and clinical presentations of VKH disease was conducted. Results Despite a list of signs that has been described as characteristic features of early or late phases of VKH disease, the current classification -developed by an international committee and published in 2001- does not consider a distinction regarding the time from onset of disease symptoms, and specific findings observed at certain time point from the symptoms presentation and outcomes related to the stage of VKH disease. In that sense, chronic recurrent VKH disease is more refractory to treatment and is associated with a higher rate of complications. Accordingly, this subset of VKH patients has poorer functional and anatomical outcomes than patients with an initial-onset acute disease. Conclusions An early clear distinction of VKH phenotype [Initial-onset acute versus chronic recurrent disease] should be considered in each clinical scenario, evaluating the delay in diagnosis and the clinical presentation, since it may help clinicians to perform a correct disease prognosis categorization and thus to make treatment decisions in terms of potential refractoriness or expected clinical outcomes.
- Standardization of Nomenclature for Ocular Tuberculosis - Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop(2020) AGRAWAL, Rupesh; AGARWAL, Aniruddha; JABS, Douglas A.; KEE, Aera; TESTI, Ilaria; MAHAJAN, Sarakshi; MCCLUSKEY, Peter J.; GUPTA, Amod; PALESTINE, Alan; DENNISTON, Alastair; BANKER, Alay; INVERNIZZI, Alessandro; FONOLLOSA, Alex; SHARMA, Aman; KUMAR, Amitabh; CURI, Andre; OKADA, Annabelle; SCHLAEN, Ariel; HEILIGENHAUS, Arnd; KUMAR, Atul; GURBAXANI, Avinash; BODAGHI, Bahram; SHAH, Bulbul Islam; LOWDER, Careen; TAPPEINER, Christoph; MUCCIOLI, Cristina; VASCONCELOS-SANTOS, Daniel Vitor; GOLDSTEIN, Debra; BEHRA, Digambar; DAS, Dipankar; MAKHOUL, Dorine; BAGLIVO, Edoardo; DENISOVA, Ekaterina; MISEROCCHI, Elisabetta; CARRENO, Ester; ASYARI, Fatma; PICHI, Francesco; SEN, H. Nida; UY, Harvey; NASCIMENTO, Heloisa; TUGAL-TUTKUN, Ilknur; AREVALO, J. Fernando; DAVIS, Janet; THORNE, Jennifer; YAMAMOTO, Joyce Hisae; SMITH, Justine; GARWEG, Justus G.; BISWAS, Jyotirmay; BABU, Kalpana; AGGARWAL, Kanika; CIMINO, Luca; KUFFOVA, Lucia; AGARWAL, Mamta; ZIERHUT, Manfred; AGARWAL, Manisha; SMET, Marc De; TOGNON, Maria Sofia; ERRERA, Marie-Helene; MUNK, Marion; WESTCOTT, Mark; SOHEILIAN, Masoud; ACCORINTI, Massimo; KHAIRALLAH, Moncef; Myhanh Nguyen; KON, Onn Minn; MAHENDRADAS, Padmamalini; YANG, Peizeng; NERI, Piergiorgio; OZDAL, Pinar; AMER, Radgonde; LEE, Richard; NORA, Rina La Distia; CHHABRA, Romi; BELFORT, Rubens; MEHTA, Salil; SHOUGHY, Samir; LUTHRA, Saurabh; MOHAMED, Shelina Oli; CHEE, Soon-Phaik; BASU, Soumyava; TEOH, Stephen; GANESH, Sudha; BARISANI-ASENBAUER, Talin; GUEX-CROSIER, Yan; OZYAZGAN, Yilmaz; AKOVA, Yonca; HABOT-WILNER, Zohar; KEMPEN, John; Quan Dong Nguyen; PAVESIO, Carlos; GUPTA, VishaliPurpose: To standardize a nomenclature system for defining clinical phenotypes, and outcome measures for reporting clinical and research data in patients with ocular tuberculosis (OTB). Methods: Uveitis experts initially administered and further deliberated the survey in an open meeting to determine and propose the preferred nomenclature for terms related to the OTB, terms describing the clinical phenotypes and treatment and reporting outcomes. Results: The group of experts reached a consensus on terming uveitis attributable to tuberculosis (TB) as tubercular uveitis. The working group introduced a SUN-compatible nomenclature that also defines disease ""remission"" and ""cure"", both of which are relevant for reporting treatment outcomes. Conclusion: A consensus nomenclature system has been adopted by a large group of international uveitis experts for OTB. The working group recommends the use of standardized nomenclature to prevent ambiguity in communication and to achieve the goal of spreading awareness of this blinding uveitis entity.
- Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality(2017) HERBORT JR., Carl P.; ASRAR, Ahmed M. Abu El; YAMAMOTO, Joyce H.; PAVESIO, Carlos E.; GUPTA, Vishali; KHAIRALLAH, Moncef; TUGAL-TUTKUN, Ilknur; SOHEILIAN, Masoud; TAKEUCHI, Masuru; PAPADIA, MarinaVogt-Koyanagi-Harada (VKH) disease is a primary autoimmune stromal choroiditis. Aim of the study was to gather a body of evidence from the literature and from experts that systemic corticosteroid combined with non-steroidal immunosuppressive therapy should become the standard of care in initial-onset VKH disease. Literature was reviewed and leading experts in VKH were consulted in different parts of the world in order to put forward a consensus attitude in the management of initial-onset VKH disease. There was a substantial body of evidence in the literature that early aggressive and sustained corticosteroid and non-steroidal immunosuppressive therapy in initial-onset VKH disease allows to achieve full control of choroidal inflammation, eliminating any subclinical choroidal inflammation, and substantially reduces recurrences with improvement of anatomical and functional outcomes. This was in agreement with experts' opinion and practice. ICGA was the method of choice to monitor disease evolution. Since the choroidal space is easily accessible to systemic therapy and because inflammation in VKH disease is exclusively originating from the choroidal stroma, early and sustained treatment right at the onset of the disease process with dual corticosteroid and non-steroidal immunosuppressive therapy can result in full ""healing"" in many cases preventing sunset glow fundus which results from depigmentation from chronic uncontrolled inflammation.